Mainly for the etiological treatment and symptomatic treatment.

2. Hypertrophic cardiomyopathy

(1) General treatment

1) The patients with no symptoms, no obvious ventricular septal hypertrophy and normal ECG were temporarily observed.

2) Avoid strenuous exercise, especially competitive sports and emotional stress.

(2) Drug treatment

Avoid using digitalis preparations, nitroglycerin, isoproterenol and other drugs.

1) Beta blockers: propranolol, aminoprolol, metoprolol, Bisoprolol.

2) Calcium antagonists: isopodine, thiazepenone.

3) Anti-heart failure treatment (end-stage) can be used diuretics and vasodilators.

4) Anti-arrhythmic: amiodarone, diisopropylamine, anti-arrhythmic and negative inotropic effects.

(3) interventricular septal muscle resection

It is suitable for patients with severe obstruction of left ventricular outflow tract who have failed drug treatment.

(4) Double chamber pacing

The prognosis is uncertain.

(5) percutaneous septal myocardial chemical ablation

In recent years, it is a new method to treat hypertrophic cardiomyopathy by injecting anhydrous ethanol into septal branch vessels supplying ventricular septal myocardial tissue to cause artificial septal myocardial infarction and relieve left ventricular outflow tract obstruction.

(6) Prevent sudden death

In high-risk patients, an implantable cardioverter defibrillator should be installed in addition to avoiding strenuous exercise and medication.

3. Restrictive cardiomyopathy

(1) Treatment of causes

For those with restricted cardiomyopathy with a clear cause, the primary disease should be treated first. For patients with eosinophilia syndrome, eosinophilia is the initial factor of the disease, resulting in endocardial and subendocardial cardiomyocytes inflammation, necrosis, mural thrombosis, embolism and other secondary changes. Therefore, treatment of eosinophilia is important to control the progression of the disease. Glucocorticoids (prednisone), cytotoxic drugs, etc., can effectively reduce eosinophilic cells and prevent the progression of endomyocardial fibrosis. Enzyme replacement therapy and gene therapy are also available for some restricted cardiomyopathy caused by genetically related enzyme deficiency.

(2) symptomatic treatment

1) Reduce ventricular filling pressure Nitric ester drugs and diuretics can effectively reduce preload, reduce pulmonary circulation and systemic circulation congestion, reduce ventricular filling pressure, alleviate symptoms, improve patients' quality of life and activity tolerance, but can not improve the long-term prognosis of patients. However, it should be noted that the myocardial stiffness of patients with restrictive cardiomyopathy increases, and the change of blood pressure is greatly affected by the change of ventricular filling pressure. Excessive reduction of preload will cause the decrease of cardiac output, the decrease of blood pressure, and the deterioration of the condition. Therefore, nitric ester drugs and diuretics should be used as appropriate according to the situation of patients. β-blockers can slow down heart rate, prolong ventricular filling time, reduce myocardial oxygen consumption, and improve ventricular diastolic function. They can be used as adjuvant therapy, but their role in the treatment of restricted cardiomyopathy is not certain.

2) Digitalis drugs with limited diastolic function have no obvious effect, but they can be used to control ventricular rate when atrial fibrillation occurs. For atrial fibrillation, amiodarone can also be used and orally prophylaxis. However, antiarrhythmic drugs are ineffective in preventing sudden death in patients with restricted cardiomyopathy, and ICD can also be inserted for treatment.

3) Anticoagulation therapy mural thrombosis and embolism are easy to occur in this disease, and anticoagulation or antiplatelet therapy can be given.

(3) Surgical treatment

For severe endocardial myocardial fibrosis, endocardial exfoliation is possible to remove the fibrous endocardial membrane. Prosthetic valve replacement is feasible for patients with valve regurgitation. Thrombectomy was performed for patients with mural thrombosis. The mortality rate is 20%. Heart transplantation may be considered for idiopathic or familial restrictive cardiomyopathy with refractory heart failure. Studies have shown that children with restricted cardiomyopathy have a greater risk of sudden death even if they do not have obvious symptoms of heart failure, so it is suggested that early heart transplantation should be performed in children with a clear diagnosis to improve the prognosis.

4. Secondary cardiomyopathy

Mainly target the etiology treatment.